These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36003768)

  • 21. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
    Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
    Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
    Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
    Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
    Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
    Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
    Parker BM; Parker JV; Lymperopoulos A; Konda V
    J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS.
    Vidrine DW; Berry JF; Garbuzov A; Falcon C; Tubbs RS; Bui CJ
    Childs Nerv Syst; 2021 Jul; 37(7):2147-2151. PubMed ID: 34014367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.
    Takeuchi K; Soda M; Togashi Y; Sugawara E; Hatano S; Asaka R; Okumura S; Nakagawa K; Mano H; Ishikawa Y
    Clin Cancer Res; 2011 May; 17(10):3341-8. PubMed ID: 21430068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inflammatory myofibroblastic tumor of the submandibular gland Harboring MSN-ALK gene fusion: A case report and literature review.
    Diao L; Li W; Jiang Q; Huang H; Zhou E; Peng B; Chen X; Zeng Z; He C
    Heliyon; 2023 Dec; 9(12):e22928. PubMed ID: 38144359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report].
    Bai H; Han Y; Niu Y; Zhang M
    Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):598-604. PubMed ID: 34344501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
    Yang Y; Zhou J; Zhou J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wu N; Song W; Liu X; Zhao S; Ding L; Mao L; Selvaggi G; Yuan X; Fu Y; Wang T; Xiao S; Zhang L
    Lancet Respir Med; 2020 Jan; 8(1):45-53. PubMed ID: 31628085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report.
    Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y
    J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
    Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
    Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
    Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
    Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report.
    Nagumo Y; Maejima A; Toyoshima Y; Komiyama M; Yonemori K; Yoshida A; Fujimoto H
    Int J Surg Case Rep; 2018; 48():1-4. PubMed ID: 29758320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaplastic Lymphoma Kinase (ALK) Inhibitors Show Activity in Colorectal Cancer With ALK Rearrangements: Case Series and Literature Review.
    Hu T; Zhan J; Li L; He Y; Lin Y; Wang J; Yu H; Xiong J; Fang Z; Deng J; Huang S; Xiang X
    Oncologist; 2024 Feb; ():. PubMed ID: 38381603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
    Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
    Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
    Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
    Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High efficacy of alectinib in a patient with advanced lung adenocarcinoma with 2 rare
    Li Y; Duan P; Guan Y; Chen Q; Grenda A; Christopoulos P; Denis MG; Guo Q
    Transl Lung Cancer Res; 2022 Jan; 11(1):100-110. PubMed ID: 35242631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
    Tong D; Chisholm J; Madden B; Ahmed M
    J Med Case Rep; 2024 Apr; 18(1):167. PubMed ID: 38594735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
    Qiu X; Montgomery E; Sun B
    Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A non-functional 5'
    Yang H; Li H; Fang Y; Li Z; Zhu J; Liu H; Lu C; Zhang X; Ma T; Zhang C
    Front Med (Lausanne); 2022; 9():979032. PubMed ID: 36275795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.